Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers dive into why scleroderma and lung hypertension weaken the heart

NCT ID NCT04610788

Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 43 adults with scleroderma or unexplained pulmonary arterial hypertension (PAH) to understand why the right side of the heart weakens. Researchers collected blood and tissue samples during routine procedures and measured heart function over 6 months. The goal was to learn how standard PAH treatment affects the heart, not to test a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

43 people

The number who actually took part.

Started

Apr 2019

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients 18 years or older with clinically diagnosed scleroderma or presumed/known idiopathic pulmonary hypertension.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients 18 years or older with clinically diagnosed scleroderma or presumed/known idiopathic pulmonary hypertension. Exclusion Criteria: * Patients found to have secondary pulmonary hypertension (PH due to left heart failure) on clinical RHC. * Hemodynamically unstable patients (systolic blood pressure \< 90mmHg, vasopressor requirement). * Patients whom are unable to give consent for themselves. * Patients with RV clot or septal aneurysm will be excluded. * In order to undergo the clinical right heart catheterization procedures, pregnancy testing (urine or serum) is standard of care. * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse scleroderma Familial Primary Pulmonary Hypertension idiopathic pulmonary arterial hypertension pulmonary arterial hypertension pulmonary systemic sclerosis scleroderma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary artery hypertension Scleroderma

Contacts and locations

Locations

  • Johns Hopkins

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.